* Previously used reporting classification. In the first half, some favorable factors led the Group to revise its objectives for 2014: Year-on-year growth of specialty care sales between 6.0% and 8.0% , driven by the strong growth of Somatuline , the solid Decapeptyl performance notably due to the….
Posted: 2014-08-29 07:26:00
